To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
Public ClinicalTrials.gov record NCT00141388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.
Study identification
- NCT ID
- NCT00141388
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 455 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1998 (Type not available)
- Primary completion
- Not listed
- Completion
- Oct 2005 (Actual)
- Last update posted
- Nov 6, 2009
1998 – 2005
United States locations
- U.S. sites
- 48
- U.S. states
- 23
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35249 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35255 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35294-0021 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85006 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85712-2809 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85712 | — |
| Pfizer Investigational Site | Little Rock | Arkansas | 72205 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | Pasadena | California | 91105 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32608-1197 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32610 | — |
| Pfizer Investigational Site | Miami | Florida | 33136 | — |
| Pfizer Investigational Site | Plantation | Florida | 33317 | — |
| Pfizer Investigational Site | Spring Hill | Florida | 34609 | — |
| Pfizer Investigational Site | Tallahassee | Florida | 32308 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60612 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62702 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62704 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46202 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46254 | — |
| Pfizer Investigational Site | Iowa City | Iowa | 52242 | — |
| Pfizer Investigational Site | Kansas City | Kansas | 66160-7314 | — |
| Pfizer Investigational Site | Kansas City | Kansas | 66160 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40205 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21201 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21224 | — |
| Pfizer Investigational Site | Greenbelt | Maryland | 20770 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02130 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48108 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109 | — |
| Pfizer Investigational Site | Saint Paul | Minnesota | 55102 | — |
| Pfizer Investigational Site | Chesterfield | Missouri | 63017 | — |
| Pfizer Investigational Site | Columbia | Missouri | 65212 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110-1092 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110 | — |
| Pfizer Investigational Site | Lebanon | New Hampshire | 03756 | — |
| Pfizer Investigational Site | New York | New York | 10016 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | Rochester | New York | 14642 | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27157 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Columbus | Ohio | 43210 | — |
| Pfizer Investigational Site | Portland | Oregon | 97227 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232 | — |
| Pfizer Investigational Site | Dallas | Texas | 75230 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Bennington | Vermont | 05201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00141388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 6, 2009 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00141388 live on ClinicalTrials.gov.